Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Ondine Biomedical Inc. is a Canadian life sciences company specializing in the development and commercialization of innovative antimicrobial therapies. The company’s principal focus is on photodisinfection, a proprietary light-based technology designed to rapidly destroy a wide range of pathogens—bacteria, viruses, yeasts, and fungi—without inducing antibiotic resistance. This technology addresses significant global health concerns, particularly the growing threat of antimicrobial resistance due to the misuse of antibiotics. Ondine Biomedical’s flagship product, Steriwave™, targets the eradication of harmful nasal pathogens linked to healthcare-associated infections (HAIs), and has been successfully implemented in clinical settings to reduce infection rates. The company maintains a robust pipeline, with additional photodisinfection-based products in various stages of research and development, including therapies for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia. Through its focus on environmentally safe, cost-effective solutions, Ondine Biomedical plays a critical role in setting new standards for infection control and public health, with applications spanning hospital, clinical, and industrial environments.